Th2-mediated anti-tumour immunity: Friend or foe?
-
Altmetric Citations
Ellyard, Julia; Simson, Ljubov; Parish, Christopher
Description
The concept that the immune system can recognise tumour cells and either eliminate them (tumour immune surveillance) or select for immunologically resistant variants (immunoediting) is gaining general acceptance by immunologists. In terms of an adaptive immune response to cancer, however, much of the research has focused on the response of cytotoxic CD8+ T lymphocytes to tumour-specific antigens and the production of Th1 cytokines by CD4+ and CD8+ T cells. In contrast, Th2-mediated immunity has...[Show more]
dc.contributor.author | Ellyard, Julia | |
---|---|---|
dc.contributor.author | Simson, Ljubov | |
dc.contributor.author | Parish, Christopher | |
dc.date.accessioned | 2015-12-07T22:49:06Z | |
dc.identifier.issn | 0001-2815 | |
dc.identifier.uri | http://hdl.handle.net/1885/26604 | |
dc.description.abstract | The concept that the immune system can recognise tumour cells and either eliminate them (tumour immune surveillance) or select for immunologically resistant variants (immunoediting) is gaining general acceptance by immunologists. In terms of an adaptive immune response to cancer, however, much of the research has focused on the response of cytotoxic CD8+ T lymphocytes to tumour-specific antigens and the production of Th1 cytokines by CD4+ and CD8+ T cells. In contrast, Th2-mediated immunity has traditionally been viewed as favouring tumour growth, both by promoting angiogenesis and by inhibiting cell-mediated immunity and subsequent tumour cell killing. While there is evidence that components of type 2 inflammation, such as B cells and interleukin-10, do promote tumour growth, there are also many studies demonstrating the anti-tumour activity of CD4+ Th2 cells, particularly in collaboration with tumour-infiltrating granulocytes, such as eosinophils. In this review, we examine all the components of type 2 immunity and their effects on tumour growth. Collectively, from this analysis, we conclude that there is a great potential for the development of Th2-mediated immunotherapies that harness the cytotoxic activity of eosinophils. | |
dc.publisher | Blackwell Publishing Ltd | |
dc.source | Tissue Antigens | |
dc.subject | Keywords: interleukin 10; interleukin 13; interleukin 4; adaptive immunity; angiogenesis; B lymphocyte; CD4+ T lymphocyte; CD8+ T lymphocyte; cell killing; cellular immunity; cytokine production; cytotoxic T lymphocyte; eosinophil; granulocyte; human; immunosurveil Cancer; Eosinophil; Th2 immunity; Tumour immune surveillance | |
dc.title | Th2-mediated anti-tumour immunity: Friend or foe? | |
dc.type | Journal article | |
local.description.notes | Imported from ARIES | |
local.identifier.citationvolume | 70 | |
dc.date.issued | 2007 | |
local.identifier.absfor | 110709 - Tumour Immunology | |
local.identifier.ariespublication | u6800332xPUB45 | |
local.type.status | Published Version | |
local.contributor.affiliation | Ellyard, Julia, College of Medicine, Biology and Environment, ANU | |
local.contributor.affiliation | Simson, Ljubov, College of Medicine, Biology and Environment, ANU | |
local.contributor.affiliation | Parish, Christopher, College of Medicine, Biology and Environment, ANU | |
local.description.embargo | 2037-12-31 | |
local.bibliographicCitation.startpage | 1 | |
local.bibliographicCitation.lastpage | 11 | |
local.identifier.doi | 10.1111/j.1399-0039.2007.00869.x | |
dc.date.updated | 2015-12-07T12:05:32Z | |
local.identifier.scopusID | 2-s2.0-34250020832 | |
Collections | ANU Research Publications |
Download
File | Description | Size | Format | Image |
---|---|---|---|---|
01_Ellyard_Th2-mediated_anti-tumour_2007.pdf | 261.49 kB | Adobe PDF | Request a copy |
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.
Updated: 17 November 2022/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator